PUBLISHER: The Insight Partners | PRODUCT CODE: 2165117
PUBLISHER: The Insight Partners | PRODUCT CODE: 2165117
According to our new research study on "Aortic Stent Grafts Market Forecast to 2034 Global Analysis - by product, end users and geography," the market is anticipated to grow from US$ 2.76 billion in 2025 to US$ 5.10 billion by 2034, with a CAGR of 7.2% during 2025-2034. The technology of anatomic aortic stent-grafts is developing into one of the important areas of technological improvement as medical device manufacturers begin to concentrate more on producing devices that can be used to treat difficult vascular anatomies, challenging aneurysm sites, and varied anatomy of the aorta.
Better perioperative results due to endovascular aortic repairs have increased the relevance of stent graft surgery for patients at higher risks from conventional open surgery. Old age, heart and lung diseases, kidney failure, frailty, among other comorbid conditions, can substantially increase the physiologic stress of open surgery for the repair of the aorta. Endovascular surgeries do not involve significant abdominal or thoracic exposure as well as operative stress, blood loss, and physiological demands for healing.
It directly influences the need for abdominal and thoracic aortic stent grafts since the criteria for selecting patients include not only anatomic factors but also operative risk. As per the ESVS guidelines, 2024, there are population-based studies in which it is noted that there is increased use of EVAR in conjunction with decreased mortality and morbidity rates even with inclusion of old and higher-risk patients in the procedure. The guideline also states that there was a significant reduction in the perioperative mortality of 21,490 patients with high-risk AAA using EVAR compared to open surgical repair. This has particular significance for manufactures as it provides scope for treating patients not suitable for open surgery.
Improvements in delivery systems, fixation methods, conformability of the graft, and fenestrated/branched devices are also assisting doctors in meeting the needs of increasingly difficult patients. While the ESVS highlights the fact that the initial survival benefits of EVAR should not overshadow the requirement of long-term monitoring and possible second procedures, this phenomenon is also prompting medical device manufacturers to innovate in creating products to extend minimally invasive procedures to increasing numbers of elderly, sickly, and anatomically difficult patients.
Improvements in delivery systems, fixation methods, conformability of the graft, and fenestrated/branched devices are also assisting doctors in meeting the needs of increasingly difficult patients. While the ESVS highlights the fact that the initial survival benefits of EVAR should not overshadow the requirement of long-term monitoring and possible second procedures, this phenomenon is also prompting medical device manufacturers to innovate in creating products to extend minimally invasive procedures to increasing numbers of elderly, sickly, and anatomically difficult patients.
Other than the major facts, Aneurysms that have ruptured present themselves as an urgent condition in which hemorrhaging may very quickly be fatal and where speed and non-invasiveness of the procedure play an important role. EVAR might allow for the achievement of aortic exclusion and hemorrhage control in a minimally invasive way without the need for the large surgical access required for open repair in anatomically feasible patients. It is thus clear that the ongoing collection of clinical data and development of emergency endovascular techniques have created a favorable environment for use of endovascular devices for emergencies.
In 2025, Medtronic reported that its Endurant stent graft system was awarded new FDA labelling, which included clinical data for treatment of ruptured abdominal aortic aneurysms, thus eliminating the former warning about its use for rAAA. According to the company, the Endurant is the first EVAR system to have received FDA labelling that incorporates clinical data about the use of rAAA. It is an important example of how the clinical and regulatory process is moving toward more widespread use of commercial endografts in emergency aneurysm repairs.
With future regulatory approval, clinical validation, and development of capabilities for emergencies, abdominal aortic stent grafts are expected to have the possibility of increasing their indications to include ruptured aneurysms. Increasing indications for rAAA procedures will increase the addressable patient population and assist in the development and commercialization of emergency compatible stents within the aortic stent graft market.
The competitive environment of the Aortic Stent Grafts Market is influenced by innovations in terms of the development of stent grafts, delivery devices, anatomical flexibility, branched and fenestrated designs, and minimally invasive treatment of the aorta. In the course of further development, manufacturers are increasingly interested in improvements in terms of graft conformability, fixation, sealing properties, accuracy of delivery and applicability in case of complicated anatomy of the aorta. In addition, product development is oriented towards low profile delivery systems, customizations, and solutions for difficult cases of thoracic, abdominal, and thoracoabdominal aortic diseases. Companies gain competitive advantages through the introduction of innovative products, their testing, receiving necessary certificates, collaboration, acquisition and penetration of the emerging healthcare markets. Increasing attention is paid to technologies used for the treatment of complicated aneurysms, aortic dissections and challenging anatomies in terms of application of traditional endovascular treatment methods. The market research is based on data received from reliable public sources, such as FDA, CMS, NIH, ESVS, SVS, NHS, national regulatory agencies, company annual reports and presentations, product brochures, clinical trials, scientific literature, and governmental healthcare agencies.